Kromann Reumert advises Investcorp on the acquisition of Sanos Group

Kromann Reumert has advised Investcorp in connection with its acquisition of 100% of shares in Sanos Group A/S ("Sanos Group"), a leading provider of specialised clinical trial services to the global pharmaceutical and biotechnology industry, from the Nordic Bioscience group.

Based in Denmark, the Sanos Group is a global Contract Research Organisation ("CRO") which comprises the two subsidiaries NBCD A/S ("NBCD") and Sanos A/S ("Sanos"); NBCD is a CRO specialised in osteoarthritis and Sanos is a site management organization focusing on lifestyle and age-related diseases. Sanos Group has built a worldwide reputation for its scientific expertise, ability to recruit patients and track record of executing efficient clinical trials.

Investcorp plans to support Sanos Group’s efforts to capitalize on its multiple market opportunities by further increasing its penetration in osteoarthritis while looking to grow into clinical trials for other therapeutic areas and expanding its research clinics network. The acquisition of Sanos Group is Investcorp’s 11th investment in the healthcare sector and the third in Europe.

Kromann Reumert has assisted the Investcorp team on all legal aspects of this transaction highlighting our strong focus and expertise within the life sciences and private equity sectors.

Please see InvestCorp's press release for further information.